Pfenex and Alvogen are expanding their collaboration to develop and commercialize Pfenex’s lead product candidate, PF708, a proprietary teriparatide therapeutic equivalent candidate to Eli Lilly & Company’s Forteo/Forsteo, to the EU, to certain countries in Middle East and North Africa (MENA) and ROW territories. This collaboration leverages Alvogen’s established international experience and expertise in regulatory, IP and supply chain activities, as well as its established network of specia...